Better survival was seen when treatment choice between chemotherapy and endocrine therapy in women with HR+/HER2- metastatic breast cancer was guided by circulating tumor cell (CTC) counts.
Medscape Medical News
CTC-guided Therapy Beats Physician Choice in Met Breast Cancer
